Mesenchymal Stem Cell-Like Properties of Orbital Fibroblasts in Graves' Orbitopathy
Kozdon K., Fitchett C., Rose GE., Ezra DG., Bailly M.
Laboratory Study on Autoimmune Research, published in Invest Ophthalmol Vis Sci (2015) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Invest Ophthalmol Vis Sci (2015)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 26325413
- PMCID
- PMC4559215
- DOI
- 10.1167/iovs.15-16580
- Citations
- 20
Abstract (original English)
Purpose Graves' orbitopathy (GO) is a sight-threatening autoimmune disorder causing extraocular muscle fibrosis, upper lid retraction and eye bulging due to orbital fat expansion. These clinical features are mediated by aspects of orbital fibroblasts differentiation, including adipogenesis and fibrosis. Our previous work suggested that this dual phenotype might be a manifestation of mixed cell populations, partially linked to the expression of mesenchymal stem cell (MSC) marker CD90. Thus, we set out to determine whether GO orbital fibroblasts displayed MSC properties. Methods Control and GO orbital fibroblasts previously characterized for CD90 and CD45 expression were analyzed by flow cytometry for classical MSC positive (CD73, CD105) and negative (CD14, CD19, HLA-DR, and CD34) markers. Graves' orbitopathy fibroblasts were tested further for their ability to undergo lineage specific differentiation following standard protocols. Results Control and GO fibroblasts strongly expressed CD73 and CD105, with a higher percentage of positive cells and stronger expression levels in GO. Neither cell type expresses CD14, CD19, and HLA-DR. Protein CD34 was expressed at low levels by 45% to 70% of the cells, with its expression significantly lower in GO cells. Graves' orbitopathy fibroblasts displayed features of osteogenesis (calcium deposits, and osteocalcin [BGLAP] and osteonectin [SPARC
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review
Systematic Review with a reported sample of 609 on Hair Loss, Immune Modulation, Autoimmune Research, published in Dermatol Reports (2026) — summary generated from the PubMed abstract.
- 2026
- n = 609
Dermatol Reports - Level ARandomized Controlled TrialPubMed
Darvadstrocel in Patients With Crohn's Disease With Complex Perianal Fistulas: The ADMIRE CD II Phase 3 Randomized Trial.
Randomized Controlled Trial with a reported sample of 283 on Autoimmune Research, published in Gastroenterology (2026) — summary generated from the PubMed abstract.
- 2026
- n = 283
Gastroenterology3 citations - Level ASystematic ReviewEurope PMC
Intraoperative Autologous Adipose-Derived Therapies and PRP as Add-On in the Surgical Treatment of Cryptoglandular and Crohn's Disease-Related Perianal Fistula-A Systematic Review
Systematic Review with a reported sample of 1017 on Autoimmune Research, published in Bioengineering (Basel) (2026) — summary generated from the PubMed abstract.
- 2026
- n = 1017
Bioengineering (Basel) - Level ASystematic ReviewEurope PMC
Cutaneous lymphatics and skin diseases: mechanisms, imaging modalities, and future therapeutic strategies
Systematic Review on Skin Aging, Chronic Inflammation, Autoimmune Research, published in Front Physiol (2026) — summary generated from the PubMed abstract.
- 2026
Front Physiol - Level ASystematic ReviewEurope PMC
Surgical interventions in inflammatory bowel disease: Indications, techniques, outcomes, and future directions
Systematic Review on Autoimmune Research, published in World J Gastrointest Pharmacol Ther (2026) — summary generated from the PubMed abstract.
- 2026
World J Gastrointest Pharmacol Ther - Level ASystematic ReviewEurope PMC
Management of Oro-Antral Communication: A Systemic Review of Diagnostic and Therapeutic Strategies
Systematic Review on Autoimmune Research, published in Diagnostics (Basel) (2025) — summary generated from the PubMed abstract.
- 2025
Diagnostics (Basel)5 citations